[
    {
        "content": "* \u200dCOURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8 497 393 OWNED BY UNITED THERAPEUTICS\u200b",
        "date": "11142017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT "
    },
    {
        "content": "* United Therapeutics Corporation reports third quarter 2017 financial results",
        "date": "10252017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics Corp reports third quarter 2017 financial results "
    },
    {
        "content": "* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system",
        "date": "10232017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system "
    },
    {
        "content": "* United Therapeutics Corporation reports second quarter 2017 financial results",
        "date": "07272017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics Corp reports Q2 EPS non-GAAP $4.37 "
    },
    {
        "content": "* United Therapeutics Corp - on May 31  2017  co entered into agreement with Citibank  N.A. relating to a collared accelerated share repurchase program",
        "date": "06012017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics enters into agreement with Citibank relating to share repurchase program "
    },
    {
        "content": "* United Therapeutics Corp - on May 17  2017  co entered into first amendment to license agreement with Eli Lilly and company",
        "date": "05182017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company "
    },
    {
        "content": "* United Therapeutics announces $250 million share repurchase program",
        "date": "04282017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics announces $250 mln share repurchase program "
    },
    {
        "content": "* United therapeutics corp-  3d systems united therapeutics today announced plans to develop solid-organ scaffolds for human transplants Source text for Eikon: Further company coverage:",
        "date": "04262017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics and 3D Systems announce bioprinting agreement "
    },
    {
        "content": "* Respira Therapeutics says entered into a strategic collaboration with united therapeutics corporation for development and exclusive license of respira's  rt234",
        "date": "04122017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-Respira Therapeutics says entered into strategic collaboration with United Therapeutics "
    },
    {
        "content": "* United Therapeutics-regulatory delays will result in postponement of planned U.S. launch of remosynch implantable system for remodulin until 2018",
        "date": "04032017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics announces regulatory delays for Remosynch Implantable Pump "
    },
    {
        "content": "* United Therapeutics announces decision from patent trial and appeal board and issuance of new patents",
        "date": "03312017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics says Patent Trial and Appeal Board found that all claims of '393 patent are not patentable "
    },
    {
        "content": "* United Therapeutics - co  Northwell Health's Feinstein Institute for Medical Research announced strategic partnership",
        "date": "03092017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics  Northwell Health's Feinstein Institute announce partnership "
    },
    {
        "content": "* United Therapeutics Corporation reports 2016 fourth quarter and annual financial results",
        "date": "02222017",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics reports Q4 non-GAAP eps of $4.12 "
    },
    {
        "content": "* United therapeutics corporation reports third quarter 2016 financial results",
        "date": "10272016",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics reports Q3 EPS $3.50 "
    },
    {
        "content": "* United therapeutics corporation reports first quarter 2016 financial results",
        "date": "04282016",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-United Therapeutics qtrly non-gaap EPS $ 3.02 "
    },
    {
        "content": "* U.S. Patent and trademark office has initiated IPR proceeding against U.S. Patent No. 8 497 393 owned by United Therapeutics  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "04112016",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "BRIEF-SteadyMed says U.S. Patent and Trademark office has initiated proceeding against patent owned by United Therapeutics "
    },
    {
        "content": "AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs.",
        "date": "08192015",
        "name": "United Therapeutics Corporation",
        "news_type": "topStory",
        "symbol": "UTHR",
        "title": "AbbVie buys special review voucher for $350 million "
    },
    {
        "content": "Aug 19 AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs.",
        "date": "08192015",
        "name": "United Therapeutics Corporation",
        "news_type": "normal",
        "symbol": "UTHR",
        "title": "AbbVie buys special review voucher for $350 mln "
    },
    {
        "content": "March 10 The U.S. Food and Drug Administration said it had approved United Therapeutics Corp's drug to treat neuroblastoma  a rare form of cancer that most often occurs in young children.",
        "date": "03102015",
        "name": "United Therapeutics Corporation",
        "news_type": "normal",
        "symbol": "UTHR",
        "title": "FDA approves United Therapeutics' drug for treating cancer in children "
    },
    {
        "content": "* Analyst expects drug to cost $150 000 per patient per year   (Adds analyst comment  background)",
        "date": "03102015",
        "name": "United Therapeutics Corporation",
        "news_type": "normal",
        "symbol": "UTHR",
        "title": "UPDATE 2-FDA approves United Therapeutics' drug for children's cancer "
    }
]